TherapeuticsMD (TXMD) Stock Price, News & Analysis

Company Overview

TherapeuticsMD, Inc. (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause. The company also markets BIJUVA, the first combination bio-identical estrogen and progesterone capsule for the treatment of moderate to severe hot flashes. In addition, TherapeuticsMD is advancing a pipeline of novel contraceptive technologies, including transdermal delivery systems and oral formulations aimed at providing more flexible dosing options.

Founded in 2015 and headquartered in Boca Raton, Florida, TherapeuticsMD has built a leadership team with extensive experience in women’s health and specialty pharmaceuticals. The organization emphasizes strategic partnerships and targeted clinical development to support product launches and lifecycle management. With a commitment to research and patient-centric care, TherapeuticsMD continues to expand its portfolio and strengthen its position in the women’s health market.

Key Stats

• Today's Range: $2.07 to $2.17
• 50-Day Range: $1.94 to $2.28
• 52-Week Range: $0.99 to $2.95
• Volume: 20,061 shs
• Average Volume: 34,259 shs
• Market Capitalization: $24.30 million
• P/E Ratio: 105.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TherapeuticsMD Stock Analysis - MarketRank™

TherapeuticsMD scored higher than 31% of companies evaluated by MarketBeat, and ranked 817th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

TherapeuticsMD has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

TherapeuticsMD has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of TherapeuticsMD is 105.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 39.02.

Price to Earnings Ratio vs. Sector

The P/E ratio of TherapeuticsMD is 105.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.82.

Price to Book Value per Share Ratio

TherapeuticsMD has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of TherapeuticsMD has been sold short.

Short Interest Ratio / Days to Cover

TherapeuticsMD has a short interest ratio ("days to cover") of 0.56, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TherapeuticsMD has recently decreased by 4.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TherapeuticsMD does not currently pay a dividend.

Dividend Growth

TherapeuticsMD does not have a long track record of dividend growth.

News and Social Media

• Score: 4.9 / 5
• News Sentiment: N/A

News Sentiment

TherapeuticsMD has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TherapeuticsMD this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for TXMD on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TherapeuticsMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of TherapeuticsMD is held by insiders.

Percentage Held by Institutions

30.74% of the stock of TherapeuticsMD is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/11/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:TXMD
• Previous Symbol: NYSEMKT:TXMD
• CIK: 25743
• Web: www.therapeuticsmd.com
• Phone: (561) 961-1900
• Fax: 561-431-3389
• Employees: 420
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): $0.02
• Trailing P/E Ratio: 105.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$570 thousand
• Net Margins: -6.64%
• Pretax Margin: -8.04%
• Return on Equity: -1.09%
• Return on Assets: -0.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.22
• Quick Ratio: 3.22

Sales & Book Value

• Annual Sales: $3.02 million
• Price / Sales: 8.05
• Cash Flow: $0.05 per share
• Price / Cash Flow: 45.44
• Book Value: $2.32 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 11,570,000
• Free Float: 11,377,000
• Market Cap: $24.30 million
• Optionable: Optionable
• Beta: 0.65